DarioHealth (NASDAQ: DRIO), a leader in the global digital health market, reported on a retrospective cohort study at the recent American Diabetes Association (“ABA”) 83rd Scientific Sessions. According to the announcement, the study analyzed real-world data of Dario users against matched controls, with results showing significant improvements in HbA1c for Dario users with serious diabetes. The Scientific Sessions were held June 23–26, 2023, in California. The announcement noted that, “in an industry first,” analysis found statistically significant reductions in HbA1c compared to matched controls across real-world user data. Further analysis revealed that when baseline HbA1c reflected more serious diabetes the difference was even greater. Specifically, the study reported a 2.3-point reduction in HbA1c for Dario digital health users with baseline HbA1c greater than 9 points. “There is a growing need to bring higher quality evidence generation in digital health,” said DarioHealth chief medical officer Omar Manejwala in the press release. “We believe that Sanofi’s new research ensures Dario is leapfrogging others in the space in terms of quality of evidence as well as clinical effect sizes. With payers rightly demanding rigor in evidence for digital health solutions, this new evidence ensures that Dario is uniquely positioned to exceed these requirements.”
To view the full press release, visit https://ibn.fm/00EcG
About DarioHealth Corp.
DarioHealth Corp. is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multichronic condition digital therapeutics platform. Dario’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health. The company’s user-centric platform offers people continuous and customized care for health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results, and making the right thing to do the easy thing to do. Dario provides its highly user-rated solutions globally to health plans and other payors, self-insured employers and providers of care as well as directly to consumers. For more information about the company, please visit www.DarioHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork
